Clinical Trials Logo

Chronic Arsenic Poisoning clinical trials

View clinical trials related to Chronic Arsenic Poisoning.

Filter by:
  • None
  • Page 1

NCT ID: NCT03127657 Completed - Clinical trials for Chronic Arsenic Poisoning

Effect of Cock's Comb Extract in the Treatment of Arsenical Skin Lesion

Start date: January 17, 2016
Phase: Phase 2
Study type: Interventional

Cock's comb extract is rich in hyaluronic acid, which is used as viscosupplementation injection and oral supplementation for osteoarthritis. Hyaluronic acid acts as humectants and topical moisturizing agent to the skin due to excellent moisturizing property. It has anti-inflammatory effect and used in the treatment of ulcer healing and to reduce the intensity of radioepithelitis. It is also used as a topical vehicle for the delivery of drug to the skin in actinic keratosis. In the case of arsenical keratotic nodule, topical application of hyaluronic acid may tends to decrease keratosis by repeated hydration of the skin. Therefore, the study will be conducted to determine any beneficial effect of topical application of cock's comb extract in the treatment of the patients with severe palmar arsenical keratosis.

NCT ID: NCT02908581 Completed - Clinical trials for Chronic Arsenic Poisoning

Effect of Iron and Folic Acid on Skin Fungal Pattern in Patients With Arsenicosis

Start date: June 2016
Phase: Phase 2
Study type: Interventional

This study will be conducted to observe any change in fungal pattern on skin of arsenicosis patients before and after administration of iron (150 mg) and folic acid (0.5 mg) tablets.

NCT ID: NCT02468518 Completed - Clinical trials for Chronic Arsenic Poisoning

Effect of Vitamin E on Skin Aerobic Bacteria in Palmar Arsenical Keratosis

Start date: March 2015
Phase: Phase 2
Study type: Interventional

This study will be conducted to observe any change in aerobic bacterial pattern on the skin of arsenicosis patients before and after administration of vitamin E (200 IU) capsules.

NCT ID: NCT02352987 Completed - Clinical trials for Chronic Arsenic Poisoning

Effect of Neem Extract, Propylene Glycol and Salicylic Acid Combination in the Treatment of Arsenical Palmar Keratosis

Start date: March 2015
Phase: Phase 2
Study type: Interventional

This study is designed to find out the effectiveness of combination of ethanol extract of neem leaf, propylene glycol (40%) and salicylic acid (10%) in the treatment of palmar arsenical keratosis.

NCT ID: NCT01748669 Completed - Clinical trials for Chronic Arsenic Poisoning

Effectiveness of Garlic Oil in the Treatment of Arsenical Palmer Keratosis

Start date: October 2011
Phase: Phase 2
Study type: Interventional

Twenty patients of mild to moderate degree of arsenical palmer keratosis will be treated with garlic oil capsule orally for 12 weeks to examine its effectiveness in reducing body arsenic load and clinical symptoms. Similar treatment with similar number of arsenic exposed controls and healthy volunteers will be included for comparison.

NCT ID: NCT01743066 Completed - Clinical trials for Chronic Arsenic Poisoning

Vitamin E Level in Buccal Cells of Arsenicosis Patients

Start date: October 2010
Phase: N/A
Study type: Interventional

To understand the pathogenesis of chronic arsenic toxicity, the investigators need to know the levels of vitamin E in patients chronically exposed to high concentration of arsenic and if changes are found, what happens when supplemented with vitamin E. The buccal cells and serum of patients will be collected for the estimation of vitamin E both before and after supplementation with vitamin E. Similar samples will be collected from similar number of arsenic exposed controls and healthy volunteers for comparison.

NCT ID: NCT01726426 Completed - Clinical trials for Chronic Arsenic Poisoning

Modulation of Anaerobic Gut Bacteria of Arsenicosis Patients by Probiotics

Start date: April 2013
Phase: N/A
Study type: Interventional

The role of anaerobic bacteria in the pathogenesis of palmer arsenical keratosis is not known. This can be evaluated by administering probiotics. Thirty patients from an arsenic affected area will be provided two probiotics capsules per day orally for 12 weeks and stool samples will be collected for qualitative and quantitative analysis of anaerobic bacteria. Similar number of arsenic exposed controls and healthy volunteers from the same area will be included with similar protocol for comparison. Like aerobic bacteria, anaerobic bacteria may be modulated by probiotics in arsenicosis patients.